Insulin-like growth factor-1 gene therapy - ValentisAlternative Names: IGF-1 gene therapy - Valentis; Somatomedin-1 gene therapy - Valentis
Latest Information Update: 31 Aug 2007
At a glance
- Originator Valentis
- Class Antihyperglycaemics; Gene therapies; Growth factors
- Mechanism of Action Gene transference; Insulin-like growth factor I stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetic neuropathies; Genitourinary disorders; Postmenopausal osteoporosis